The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education
- PMID: 26283480
- DOI: 10.4049/jimmunol.1401811
The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education
Abstract
NK cells play an important role in the defense against viral infections. However, little is known about the regulation of NK cell responses during the first days of acute viral infections in humans. In this study, we used the live attenuated yellow fever virus (YFV) vaccine 17D as a human in vivo model to study the temporal dynamics and regulation of NK cell responses in an acute viral infection. YFV induced a robust NK cell response in vivo, with an early activation and peak in NK cell function at day 6, followed by a delayed peak in Ki67 expression, which was indicative of proliferation, at day 10. The in vivo NK cell response correlated positively with plasma type I/III IFN levels at day 6, as well as with the viral load. YFV induced an increased functional responsiveness to IL-12 and IL-18, as well as to K562 cells, indicating that the NK cells were primed in vivo. The NK cell responses were associated primarily with the stage of differentiation, because the magnitude of induced Ki67 and CD69 expression was distinctly higher in CD57(-) NK cells. In contrast, NK cells expressing self- and nonself-HLA class I-binding inhibitory killer cell Ig-like receptors contributed, to a similar degree, to the response. Taken together, our results indicate that NK cells are primed by type I/III IFN in vivo early after YFV infection and that their response is governed primarily by the differentiation stage, independently of killer cell Ig-like receptor/HLA class I-mediated inhibition or education.
Copyright © 2015 by The American Association of Immunologists, Inc.
Similar articles
-
The early cellular signatures of protective immunity induced by live viral vaccination.Eur J Immunol. 2012 Sep;42(9):2363-73. doi: 10.1002/eji.201142306. Epub 2012 Aug 6. Eur J Immunol. 2012. PMID: 22733156
-
Type III Interferon-Mediated Signaling Is Critical for Controlling Live Attenuated Yellow Fever Virus Infection In Vivo.mBio. 2017 Aug 15;8(4):e00819-17. doi: 10.1128/mBio.00819-17. mBio. 2017. PMID: 28811340 Free PMC article.
-
Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.J Immunol. 2021 Aug 15;207(4):1033-1043. doi: 10.4049/jimmunol.2001381. Epub 2021 Jul 28. J Immunol. 2021. PMID: 34321231 Free PMC article.
-
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models.Viruses. 2017 Apr 11;9(4):77. doi: 10.3390/v9040077. Viruses. 2017. PMID: 28398253 Free PMC article. Review.
-
Activation of natural killer cells: underlying molecular mechanisms revealed.Scand J Immunol. 2004 Jul-Aug;60(1-2):14-22. doi: 10.1111/j.0300-9475.2004.01475.x. Scand J Immunol. 2004. PMID: 15238069 Review.
Cited by
-
Influenza Vaccination Generates Cytokine-Induced Memory-like NK Cells: Impact of Human Cytomegalovirus Infection.J Immunol. 2016 Jul 1;197(1):313-25. doi: 10.4049/jimmunol.1502049. Epub 2016 May 27. J Immunol. 2016. PMID: 27233958 Free PMC article.
-
Natural killer cells and unconventional T cells in COVID-19.Curr Opin Virol. 2021 Aug;49:176-182. doi: 10.1016/j.coviro.2021.06.005. Epub 2021 Jun 19. Curr Opin Virol. 2021. PMID: 34217135 Free PMC article. Review.
-
NKG2C+CD57+ natural killer cells with senescent features are induced during cutaneous leishmaniasis and accumulate in patients with lesional healing impairment.Clin Exp Immunol. 2024 Aug 9;217(3):279-290. doi: 10.1093/cei/uxae040. Clin Exp Immunol. 2024. PMID: 38700066
-
Durable natural killer cell responses after heterologous two-dose Ebola vaccination.NPJ Vaccines. 2021 Jan 29;6(1):19. doi: 10.1038/s41541-021-00280-0. NPJ Vaccines. 2021. PMID: 33514756 Free PMC article.
-
Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses.J Clin Invest. 2020 Jul 1;130(7):3936-3946. doi: 10.1172/JCI132438. J Clin Invest. 2020. PMID: 32315287 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous